AcademiaDrive research excellence and student success
Drive research excellence and student success
GovernmentData-driven solutions for public sector challenges
Data-driven solutions for public sector challenges
Intellectual PropertyTransform the way you create, manage and protect intellectual property
Transform the way you create, manage and protect intellectual property
Life Sciences & HealthcareAdvance innovation and accelerate patient outcomes
Advance innovation and accelerate patient outcomes
Scientific & Academic Researcharrow_forward
Discovery & Workflow
Analytics, Evaluation & Management
Publishing
Libraries, Teaching & Learning
Biopharma Intelligencearrow_forward
Research & Development
Pharmacovigilance & Drug Safety
Regulatory & Compliance
Portfolio Strategy & Business Development
Commercial & Launch Strategy
Generics & Manufacturing
Market Access
Customer Engagement
Medtech Intelligencearrow_forward
Strategic Portfolio Planning
Launch Strategy
Commercial Effectiveness
Product Lifecycle Management
IP Intelligencearrow_forward
IP Litigation Intelligence Solutions
Patent Intelligence Software
Patent Search & Analytics
Trademark Research & Protection
Chemistry & Life Science
IP Data & APIs
IP Lifecycle Managementarrow_forward
IP Management Software
Network Collaboration Tools
IP Servicesarrow_forward
Patent & Trademark Maintenance
Filing & Prosecution Support
Patent Translations Services
Consulting & Dataarrow_forward
Consulting Services
Data integration and custom analytics
Real-World Data
Research Reports
Market Intelligence Data
Life Sciences and Healthcare Consulting Services
BlogKeep up with the latest news, insights and research from Clarivate.
Keep up with the latest news, insights and research from Clarivate.
Clarivate Innovation ExchangeThe Clarivate Innovation Exchange accelerates research, development and commercialization.
The Clarivate Innovation Exchange accelerates research, development and commercialization.
Partnersarrow_forwardPartner with us and help accelerate innovation.
Partner with us and help accelerate innovation.
Channel Partner Program
Cortellis Partner Program
ScholarOne Partner Program
Researcher RecognitionWorld-changing research should be seen, shared and celebrated.
World-changing research should be seen, shared and celebrated.
Webinarsarrow_forward
Academic & Government
Life Sciences & Healthcare
Intellectual Property
Trademarks
Patents
IP Litigation
Reports & Case Studiesarrow_forward
Artificial Intelligence
ISI Publications
ISI Global Research Reports
PodcastsThe Clarivate podcast series enables us to address issues in key business areas in new and interesting ways.
The Clarivate podcast series enables us to address issues in key business areas in new and interesting ways.
Academia
Government
Scientific & Academic Research
Biopharma Intelligence
Medtech Intelligence
IP Intelligence
IP Lifecycle Management
IP Services
Consulting & Data
Blog
Clarivate Innovation Exchange
Partners
Researcher Recognition
Webinars
Reports & Case Studies
Podcasts
About us
Executive Leadership
Newsroom
Voice of Customer
Customer Stories
Sustainability
Support
Outline
• Sandoz's biosimilar filgrastim development program
• Zarzio's European performance
• U.S. oncologists' expected uptake of biosimilar filgrastim
• U.S. payers' price expectations and strategy to drive uptake
• Competitive landscape for biosimilars in the United States
• Potential differentiation strategies
• Next milestones for the U.S. biosimilar market
• Q&A
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 696 currently available and novel biosimilar products, detailing…
In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…
In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (…
In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…